
Sign up to save your podcasts
Or
There are cancers that grow slowly. There are cancers that do not grow at all. And then there are cancer's like today's subject, that are notorious not just for their ability to completely overcome a patient in a very small amount of time. Extensive-stage small cell lung cancer remains a very difficult condition to treat, highly prone to relapse and with few effective options beyond - or perhaps even including - the first line setting. While the medical and scientific community remain stalwart in their quest for therapeutic options, success stories have been few and far between. In this episode, Josh and Michael look at one success story, and one study dredged up from the pre-Internet era, to illustrate the dichotomy and discuss the challenge of treating this, the most aggressive of solid tumours.
Links to studies discussed in this episode (subscription may be required):
IMpower133: https://www.nejm.org/doi/full/10.1056/nejmoa1809064
von Pawel et al.: https://ascopubs.org/doi/10.1200/JCO.1999.17.2.658?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
4.5
44 ratings
There are cancers that grow slowly. There are cancers that do not grow at all. And then there are cancer's like today's subject, that are notorious not just for their ability to completely overcome a patient in a very small amount of time. Extensive-stage small cell lung cancer remains a very difficult condition to treat, highly prone to relapse and with few effective options beyond - or perhaps even including - the first line setting. While the medical and scientific community remain stalwart in their quest for therapeutic options, success stories have been few and far between. In this episode, Josh and Michael look at one success story, and one study dredged up from the pre-Internet era, to illustrate the dichotomy and discuss the challenge of treating this, the most aggressive of solid tumours.
Links to studies discussed in this episode (subscription may be required):
IMpower133: https://www.nejm.org/doi/full/10.1056/nejmoa1809064
von Pawel et al.: https://ascopubs.org/doi/10.1200/JCO.1999.17.2.658?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
30,906 Listeners
315 Listeners
3,327 Listeners
111,568 Listeners
56,111 Listeners
6,458 Listeners
43 Listeners
316 Listeners
510 Listeners
320 Listeners
54 Listeners
15,347 Listeners
63 Listeners
166 Listeners
36 Listeners